Andrew Ramelmeier - Adverum Biotechnologies Chief Officer
| ADVM Stock | USD 6.04 0.29 5.04% |
Executive
Andrew Ramelmeier is Chief Officer of Adverum Biotechnologies
| Age | 62 |
| Address | 100 Cardinal Way, Redwood City, CA, United States, 94063 |
| Phone | 650 656 9323 |
| Web | https://adverum.com |
Adverum Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.2983) % which means that it has lost $0.2983 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7626) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies' management efficiency ratios could be used to measure how well Adverum Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to drop to -0.71. In addition to that, Return On Capital Employed is likely to grow to -0.79. At this time, Adverum Biotechnologies' Total Assets are very stable compared to the past year. As of the 24th of November 2024, Non Currrent Assets Other is likely to grow to about 1.3 M, while Other Current Assets are likely to drop about 4.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alpa Parikh | Lumos Pharma | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| MD FAAP | Lumos Pharma | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Eddie MBA | Lumos Pharma | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Nicole Esq | HCW Biologics | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.3 |
Adverum Biotechnologies Leadership Team
Elected by the shareholders, the Adverum Biotechnologies' board of directors comprises two types of representatives: Adverum Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adverum. The board's role is to monitor Adverum Biotechnologies' management team and ensure that shareholders' interests are well served. Adverum Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adverum Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laurent Fischer, CEO President | ||
| Jim Wang, Chief Officer | ||
| Andrew Ramelmeier, Chief Officer | ||
| Romuald Corbau, Chief Officer | ||
| Kalliopi MD, Senior Development | ||
| Michael Steel, Senior Quality | ||
| Rabia MD, Chief Officer | ||
| Brigit Riley, Chief Officer | ||
| Setareh PharmD, Chief Officer | ||
| John JD, Senior Counsel | ||
| Linda MA, Principal CFO | ||
| Anand Reddi, VP Engagement | ||
| Dena House, Organizational Resources | ||
| Heikki Jouttijarvi, Senior Operations | ||
| Kishor JD, Chief Officer | ||
| Nancy Pecota, Principal Officer | ||
| Bill PharmD, Senior Operations | ||
| Carla Fiankan, Senior Affairs |
Adverum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adverum Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (29.22) % | ||||
| Current Valuation | 45.67 M | ||||
| Shares Outstanding | 20.8 M | ||||
| Shares Owned By Insiders | 11.67 % | ||||
| Shares Owned By Institutions | 79.15 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Earning | (2.10) X | ||||
| Price To Book | 0.87 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.